Clinical trial
Post-Marketing Surveillance of Safety and Effectiveness of Iclusig® Tablets in Korean Patients With CML or Ph+ ALL Under the "Risk Management Plan"
NCT03709017 is registered in ClinicalTrials.gov with Korea Otsuka Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post-Marketing Surveillance of Safety and Effectiveness of Iclusig® Tablets in Korean Patients With CML or Ph+ ALL Under the "Risk Management Plan"
- Lead sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- August 7, 2018
- Completion date
- June 30, 2023
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic myeloid leukemia, philadelphia chromosome-positive acute lymphoblastic leukemia